Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 26 peer-reviewed journal articles Updated
Oculoplastic Surgery

Personalized Treatment: Targeting the True Cause

At a Glance

Chronic dacryoadenitis is not treated the same way in every patient: doctors identify the cause and rule out infection before using steroids or other immune-suppressing medicines. Tumors and lymphoma require different specialist treatments.

Treatment for chronic dacryoadenitis is not “one size fits all.” Because the swelling can be caused by anything from a simple immune reaction to a complex systemic disease or even a tumor, your care team must tailor your treatment to the specific findings of your biopsy and scans [1][2].

The First Line: Systemic Corticosteroids

For cases of nonspecific orbital inflammation (NSOI) or confirmed autoimmune-related swelling, an initial step is often systemic corticosteroids (like prednisone) [3][4].

  • How They Work: These medications are powerful anti-inflammatories that can reduce swelling and pressure in the eye socket [4].
  • The Taper: Doctors rarely stop steroids abruptly. Instead, they use a taper, slowly lowering the dose over time [3][5]. Never change your dose or stop taking steroids without your clinician’s direction.
  • Limitations: While effective, steroids can have side effects (mood changes, elevated blood sugar, bone loss), and some conditions (especially IgG4-related disease) have a high rate of relapse once the steroid dose is lowered [6][7].

Escalating Care: Steroid-Sparing and B-Cell Therapies

If your swelling returns during the taper or if you cannot tolerate steroids, your doctor may recommend diagnosis-specific “steroid-sparing” agents:

  • Conventional Immunosuppressants: Medications like methotrexate, azathioprine, or mycophenolate mofetil are sometimes used to maintain remission in chronic or relapsing cases [8][9]. They require monitoring of liver and kidney function and blood counts.
  • B-Cell Depletion (Rituximab): This is a targeted therapy often used for IgG4-related disease or refractory inflammation [10]. It works by removing specific B-cells. Before starting, patients must be screened for Hepatitis B to prevent serious reactivation [11][7].

A Critical Warning: Ruling Out Infection

It is dangerous to start high-dose steroids or immunosuppression if an active infection is present, as it can allow an infection to spread rapidly [12][13].

Based on your risk, history, and pathology, doctors evaluate for:

  • Tuberculosis (TB): TB can mimic chronic dacryoadenitis and requires specific antibiotics, not steroids [12][14].
  • Abscesses: A bacterial infection with a pocket of pus (abscess) needs drainage and targeted antibiotics [15][16].
  • Viral Infections: Certain viruses, like EBV, can rarely be involved and require evaluation [17][18].
    (Note: Specialists may sometimes use steroids as an adjunct after appropriate antimicrobials are started).

When the Diagnosis Changes: Tumors and Lymphoma

If your biopsy reveals a tumor or lymphoma rather than inflammation, the treatment strategy changes fundamentally [19][20]:

  • Lymphoma: Low-grade lymphomas (like MALT) may be treated with observation, external-beam radiotherapy, or systemic therapy depending on the stage and hematologic evaluation [21][22].
  • Epithelial Tumors: Benign tumors like pleomorphic adenomas require complete surgical removal; leaving a small piece behind can lead to recurrence [23][24]. Malignant tumors often require “multimodal” treatment, including surgery followed by radiation and sometimes chemotherapy [25][26].

Your Multidisciplinary Care Team

Because chronic dacryoadenitis often involves the whole body, you may be cared for by several specialists working together [19]:

  1. Oculoplastic Surgeon: Specializes in the eye socket and performs biopsies or tumor removals.
  2. Rheumatologist: Manages long-term immunosuppression for autoimmune or IgG4-related diseases.
  3. Pathologist: The specialist who analyzes your tissue samples to provide the final diagnosis.
  4. Oncologist or Hematologist: Involved if the biopsy shows lymphoma or a malignant tumor [19][20].

Coordinating care between these specialists ensures that both your eye and your overall health are being monitored.

Common questions in this guide

What treatment is usually started for chronic dacryoadenitis?
When chronic dacryoadenitis is caused by nonspecific orbital inflammation or an autoimmune condition, doctors often start systemic corticosteroids such as prednisone. The dose is usually reduced gradually rather than stopped suddenly, and the plan depends on biopsy, scan, and infection results.
Why does infection need to be ruled out before steroid treatment?
Steroids and other immune-suppressing medicines can allow an active infection to spread. Doctors may assess for tuberculosis, an abscess, or certain viral infections; bacterial abscesses may need drainage and antibiotics, while tuberculosis requires specific antibiotic treatment.
What happens if the swelling returns while steroids are being reduced?
If swelling returns or steroids cause troublesome side effects, a clinician may consider steroid-sparing medicines such as methotrexate, azathioprine, mycophenolate mofetil, or rituximab for selected causes. These treatments require blood tests and other monitoring, and rituximab requires hepatitis B screening.
How does treatment change if a biopsy finds lymphoma or another tumor?
Treatment changes if a biopsy shows lymphoma or another tumor instead of inflammation. Depending on the tumor type and stage, options may include observation, radiotherapy, systemic treatment, or complete surgical removal; malignant tumors may need combined treatments.
Which specialists may be involved in chronic dacryoadenitis care?
Care may involve an oculoplastic surgeon for the orbit and biopsy, a rheumatologist for immune-related disease, a pathologist to analyze tissue, and an oncologist or hematologist if cancer is found. Coordinating these specialists helps monitor both eye health and overall health.
What side effects and monitoring are important during treatment?
Steroids can cause mood changes, high blood sugar, and bone loss, while immune-suppressing medicines may require monitoring of blood counts, liver function, and kidney function. Ask your clinician how symptoms, laboratory results, infection risk, and medication side effects will be followed.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the specific goal of the treatment you are recommending, and what alternatives exist?
  2. 2.Has an infection been adequately assessed before we consider immunosuppressive medications?
  3. 3.What are the major side effects of the medication prescribed, and how will we monitor for them?
  4. 4.If my symptoms worsen while tapering off steroids, what is our backup plan?
  5. 5.Which specialists will be coordinating my care moving forward?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (26)
  1. 1

    The role of biopsy in lacrimal gland inflammation: A clinicopathologic study.

    Luemsamran P, Rootman J, White VA, et al.

    Orbit (Amsterdam, Netherlands) 2017; (36(6)):411-418 doi:10.1080/01676830.2017.1352608.

    PMID: 28816552
  2. 2

    Consensus on Diagnostic Criteria of Idiopathic Orbital Inflammation Using a Modified Delphi Approach.

    Mombaerts I, Bilyk JR, Rose GE, et al.

    JAMA ophthalmology 2017; (135(7)):769-776 doi:10.1001/jamaophthalmol.2017.1581.

    PMID: 28570731
  3. 3

    Clinical characteristics, histopathology, and treatment outcomes in adult and pediatric patients with nonspecific orbital inflammation.

    Eshraghi B, Sonbolestan SA, Abtahi MA, Mirmohammadsadeghi A

    Journal of current ophthalmology 2019; (31(3)):327-334 doi:10.1016/j.joco.2019.03.004.

    PMID: 31528770
  4. 4

    Idiopathic Posterior Scleritis Complicated by Optic Perineuritis and Ocular Motility Disorder Successfully Controlled with Adalimumab: A Case Report.

    Numaga Y, Aoyama Y, Tanaka R

    Case reports in ophthalmology 2025; (16(1)):916-925 doi:10.1159/000549539.

    PMID: 41404192
  5. 5

    Man with a Swollen Eye: Nonspecific Orbital Inflammation in an Adult in the Emergency Department.

    Zhang XC, Statler B, Suner S, et al.

    The Journal of emergency medicine 2018; (55(1)):110-113 doi:10.1016/j.jemermed.2018.04.001.

    PMID: 29716820
  6. 6

    Clinicoserological factors associated with response to steroid treatment and recurrence in patients with IgG4-related ophthalmic disease.

    Hong JW, Kang S, Song MK, et al.

    The British journal of ophthalmology 2018; (102(11)):1591-1595 doi:10.1136/bjophthalmol-2017-311519.

    PMID: 29420193
  7. 7

    Ophthalmic manifestations in IgG4-related disease: Clinical presentation and response to treatment in a French case-series.

    Ebbo M, Patient M, Grados A, et al.

    Medicine 2017; (96(10)):e6205 doi:10.1097/MD.0000000000006205.

    PMID: 28272212
  8. 8

    Long-Term Outcomes of IgG4-Related Ophthalmic Disease in a Chinese IgG4-Related Disease Cohort.

    Gan L, Luo X, Fei Y, et al.

    Frontiers in medicine 2021; (8()):784520 doi:10.3389/fmed.2021.784520.

    PMID: 34977087
  9. 9

    Management of IgG4-Related Disease.

    Hernández-Molina G, Anaya-Macías BU, Martín-Nares E

    Current rheumatology reports 2026; (28(1)).

    PMID: 42096015
  10. 10

    Long-term follow up of systemic rituximab therapy as first-line and salvage therapy for idiopathic orbital inflammation and review of the literature.

    Abou-Hanna JJ, Tiu Teo HM, Thangavel R, et al.

    Orbit (Amsterdam, Netherlands) 2022; (41(3)):297-304 doi:10.1080/01676830.2021.1874424.

    PMID: 33478316
  11. 11

    The treatment outcomes in IgG4-related orbital disease: a systematic review of the literature.

    Detiger SE, Karim AF, Verdijk RM, et al.

    Acta ophthalmologica 2019; (97(5)):451-459 doi:10.1111/aos.14048.

    PMID: 30734497
  12. 12

    Bilateral Dacryoadenitis: Don't Forget Tuberculosis!

    Ruman-Colombier M, Crisinel PA, Cohen-Dumani N, et al.

    The Pediatric infectious disease journal 2017; (36(1)):117-119 doi:10.1097/INF.0000000000001365.

    PMID: 27956729
  13. 13

    Late onset paediatric dacryoadenitis associated with SARS-CoV-2 confirmed by histological analysis.

    Yokoyama K, Sato Y, Suimon Y, Kase S

    BMJ case reports 2024; (17(12)) doi:10.1136/bcr-2023-257615.

    PMID: 39694657
  14. 14

    Tuberculosis presenting as dacryoadenitis in the USA.

    Powers HR, Diaz MA, Mendez JC

    BMJ case reports 2019; (12(11)) doi:10.1136/bcr-2019-231694.

    PMID: 31748361
  15. 15

    Lacrimal gland abscesses: Case series and literature review.

    Savoie B, Rodgers R, Gorski M

    Orbit (Amsterdam, Netherlands) 2017; (36(6)):428-432 doi:10.1080/01676830.2017.1337205.

    PMID: 28812417
  16. 16

    Gonococcal Dacryoadenitis: A Case Report.

    Hains L, Quigley C, Selva D

    Case reports in ophthalmology 2026; (17(1)):275-280 doi:10.1159/000550844.

    PMID: 41884366
  17. 17

    Atypical presentation of bilateral Epstein-Barr virus dacryoadenitis: a case report of corticosteroid resistant orbital inflammation.

    Tan CH, Tauchi-Nishi PS, Sweeney AR

    Journal of ophthalmic inflammation and infection 2023; (13(1)):24 doi:10.1186/s12348-023-00349-y.

    PMID: 37173558
  18. 18

    Atypical presentation of Epstein-Barr virus infectious mononucleosis with bilateral dacryoadenitis in an elderly patient: a case report.

    Mahfoud N, Ali M, Abboud M

    Journal of medical case reports 2026; (20(1)).

    PMID: 42192474
  19. 19

    Mucosa-associated lymphoid tissue lymphoma of the lacrimal gland: A case report and literature review.

    Zhong Q, Yan Y, Li S

    Medicine 2024; (103(21)):e38303 doi:10.1097/MD.0000000000038303.

    PMID: 38787969
  20. 20

    The Lacrimal System.

    Kumar S, Kinde B, Pham N, Fischbein N

    Radiologic clinics of North America 2026; (64(4)):675-690 doi:10.1016/j.rcl.2026.02.006.

    PMID: 42230056
  21. 21

    Clinical presentation and treatment outcomes of primary ocular adnexal MALT lymphoma in Thailand.

    Seresirikachorn K, Norasetthada L, Ausayakhun S, et al.

    Blood research 2018; (53(4)):307-313 doi:10.5045/br.2018.53.4.307.

    PMID: 30588468
  22. 22

    Lymphoma of the Lacrimal Gland - An International Multicenter Retrospective Study.

    Vest SD, Mikkelsen LH, Holm F, et al.

    American journal of ophthalmology 2020; (219()):107-120 doi:10.1016/j.ajo.2020.06.015.

    PMID: 32574779
  23. 23

    Recurrent lacrimal gland pleomorphic adenoma.

    Reilly S, Ellard R, O'Sullivan M, et al.

    Orbit (Amsterdam, Netherlands) 2023; (42(6)):635-640 doi:10.1080/01676830.2022.2064515.

    PMID: 35546531
  24. 24

    Pleomorphic adenoma of the lacrimal gland: A review with updates on malignant transformation and molecular genetics.

    Harrison W, Pittman P, Cummings T

    Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society 2018; (32(1)):13-16 doi:10.1016/j.sjopt.2018.02.014.

    PMID: 29755265
  25. 25

    Long-Term Outcomes of Eye-Sparing Surgery for Adenoid Cystic Carcinoma of Lacrimal Gland.

    Han J, Kim YD, Woo KI, Sobti D

    Ophthalmic plastic and reconstructive surgery 2018; (34(1)):74-78 doi:10.1097/IOP.0000000000000877.

    PMID: 28221296
  26. 26

    Primary Ductal Her-2 Positive Adenocarcinoma of Salivary Gland: A Long Follow-Up Case Report and Review of the Literature.

    Deantoni CL, Midulla M, Mirabile A, et al.

    Case reports in ophthalmological medicine 2024; (2024()):4410206 doi:10.1155/2024/4410206.

    PMID: 39301249

This page is for informational purposes only and does not constitute medical advice. Your eye specialist and other treating clinicians must confirm the cause of chronic dacryoadenitis and choose the safest treatment and monitoring plan for you.

Get notified when new evidence is published on chronic dacryoadenitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.